P
Pablo Tamayo
Researcher at University of California, San Diego
Publications - 185
Citations - 117545
Pablo Tamayo is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Gene. The author has an hindex of 72, co-authored 177 publications receiving 97318 citations. Previous affiliations of Pablo Tamayo include University of California, Berkeley & Harvard University.
Papers
More filters
Journal ArticleDOI
The limitations of simple gene set enrichment analysis assuming gene independence
TL;DR: The results provide strong empirical evidence that gene–gene correlations cannot be ignored due to the significant variance inflation they produced on the enrichment scores and should be taken into account when estimating gene set enrichment significance.
Journal ArticleDOI
Predicting Relapse in Patients With Medulloblastoma by Integrating Evidence From Clinical and Genomic Features
Pablo Tamayo,Yoon Jae Cho,Aviad Tsherniak,Heidi Greulich,Lauren Ambrogio,Netteke Schouten van Meeteren,Tianni Zhou,Allen Buxton,Marcel Kool,Matthew Meyerson,Scott L. Pomeroy,Jill P. Mesirov +11 more
TL;DR: It is shown how integration of high-level clinical and genomic features or risk factors, including disease subtype, can yield more comprehensive, accurate, and biologically interpretable prediction models for relapse versus no-relapse classification.
Journal ArticleDOI
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells
Philip L. De Jager,Elizabeth J. Rossin,Saumyadipta Pyne,Pablo Tamayo,Linda Ottoboni,Vissia Viglietta,Mira Weiner,Dulce Soler,Elena S. Izmailova,Lauren Faron-Yowe,Carmeline O’Brien,Samuel S. Freeman,Susana Granados,Alex Parker,Ronenn Roubenoff,Jill P. Mesirov,Samia J. Khoury,David A. Hafler,Howard L. Weiner +18 more
TL;DR: Large-scale immunophenotyping approach has yielded robust evidence for a reduction of CD8(low)CD4(-) cells in both CIS and RRMS in the absence of treatment as well as suggestive evidence for the existence of immunologically distinct subsets of subjects with a demyelinating disease.
Journal ArticleDOI
Systematic Interrogation of 3q26 Identifies TLOC1 and SKIL as Cancer Drivers
Daniel Hägerstrand,Alexander B. Tong,Steven E. Schumacher,Nina Ilic,Rhine R. Shen,Hiu Wing Cheung,Francisca Vazquez,Yashaswi Shrestha,So Young Kim,Andrew O. Giacomelli,Joseph Rosenbluh,Anna C. Schinzel,Nicole Spardy,David A. Barbie,Craig H. Mermel,Barbara A. Weir,Levi A. Garraway,Pablo Tamayo,Jill P. Mesirov,Rameen Beroukhim,William C. Hahn +20 more
TL;DR: These studies identify TLOC1 and SKIL as driver genes in 3q26 and suggest that cooperating genes may be coamplified in other regions with somatic copy number gain, providing evidence that regions of somaticcopy number gain may harbor cooperating genes of different but complementary functions.
Journal ArticleDOI
Combining Gene Expression Profiles and Clinical Parameters for Risk Stratification in Medulloblastomas
Ana Fernandez-Teijeiro,Rebecca A. Betensky,Lisa Marie Sturla,John Y.H. Kim,Pablo Tamayo,Scott L. Pomeroy +5 more
TL;DR: Gene expression profiling predicts medulloblastoma outcome independent of clinical variables, and univariate analysis demonstrated expression profiles to be the only significant clinical prognostic factor.